SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMNR - Immune Response
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Nagaraju R. Arakotaram who wrote ()5/8/1998 12:42:00 PM
From: jake burns  Read Replies (1) of 1510
 
The Prudential analyst set a 12-month target price of 22 dollars per share, but emphasized this projection was conservative. The conservatism resulted from a very low market penetration estimate: 5% of IMNR's goal in the year 2000; and 25% of IMNR's goal in the year 2001. The analyst also used the low end of the range of the price IMNR will charge for the drug. The upshot is that, even with all this conservatism, Prudential feels the stock is worth 22 dollars in 12 months!!!! By the way, I expect at least 1 corporate partnership to be announced by the annual meeting in early june. Good luck to all.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News